Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports

AbstractBackground5–10% of thyroid cancers are at locally advanced stage. Neoadjuvant targeted therapy will likely create surgical opportunities for these patients with unresectable or borderline resectable tumors. Pralsetinib, a RET inhibitor, has been approved for advanced or metastatic RET-altere...

Full description

Saved in:
Bibliographic Details
Published in:Oral oncology 2024-12, Vol.159, p.107014-107014, Article 107014
Main Authors: Huang, Nai-Si, Chen, Jia-Ying, Meng, Yan, Li, Qiu-Li, Ji, Qing-Hai, Wang, Yu
Format: Article
Language:English
Subjects:
Adult
Differentiated thyroid carcinoma
Female
Hematology, Oncology, and Palliative Medicine
Humans
Male
Middle Aged
Neoadjuvant therapy
Neoadjuvant Therapy - methods
Otolaryngology
Papillary thyroid carcinoma
Pralsetinib
Proto-Oncogene Proteins c-ret - genetics
Pyrazoles - therapeutic use
Pyridines - therapeutic use
Pyrimidines
RET-fusion
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - pathology
Thyroid Neoplasms - therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AbstractBackground5–10% of thyroid cancers are at locally advanced stage. Neoadjuvant targeted therapy will likely create surgical opportunities for these patients with unresectable or borderline resectable tumors. Pralsetinib, a RET inhibitor, has been approved for advanced or metastatic RET-altered thyroid cancer. However, there is no evidence on the efficacy of pralsetinib as neoadjuvant therapy in locally advanced RET-altered thyroid cancer. Case reportTwo patients with locally advanced pappilary thyroid carcinoma (PTC) were treated with pralsetinib (400 mg daily) to reduce tumor size and increase the chance of R0 resection. Both PTCs, characterized by RET-fusion, underwent successful R0 resection without major surgical complications after 4-months neoadjuvant pralsetinib. ConclusionThere is a potential for pralsetinib as a neoadjuvant treatment in PTC with RET-fusion.
ISSN:1368-8375
1879-0593
1879-0593
DOI:10.1016/j.oraloncology.2024.107014